<div><div></div><div><span><ul><li><span>According to estimates from 6 analysts, Design Therapeutics, Inc. stock's average price target has risen from $19.33 to $20, with forecasts ranging from $15 to $22 per share</span></li><li><span>Based on the May 15 closing price, the updated target implies approximately 39% potential upside</span></li><li><span>Consensus rating remains at “Buy” across 7 covering analysts, with 7 Buys, 0 Holds and 0 Sells</span></li></ul><p><span>Explore more price target data and ratings for Design Therapeutics, Inc. on the </span><span>, and track all previous and future analyst recommendations for Design Therapeutics, Inc. in the dedicated </span>News Flow<span>.</span></p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.</span></div></section></span></div></div>

DSGN

SBIO

ARKG

LABU

<p>Design Therapeutics, Inc. stock's 12-month price target has been raised to $20, indicating a 39% upside from the previous average of $19.33. Analysts' forecasts range from $15 to $22 per share. The consensus rating remains a 'Buy' with 7 analysts recommending buys and none holding or selling.</p>

TradingView

Design Therapeutics

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Factset Research

Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside